<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="365080">
  <stage>Registered</stage>
  <submitdate>10/10/2013</submitdate>
  <approvaldate>21/10/2013</approvaldate>
  <actrnumber>ACTRN12613001162707</actrnumber>
  <trial_identification>
    <studytitle>Effect of prandial status on capillary - venous glucose gradient in type 1 diabetes </studytitle>
    <scientifictitle>Effect of prandial status on [capillary-venous] glucose difference, in participants with well controlled type 1 diabetes </scientifictitle>
    <utrn> U1111-1148-9772 </utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Capillary and venous glucose responses will be measured one hour and two hours after a buffet breakfast, the content of which is selected by participants. Total period of observation is two hours.   </interventions>
    <comparator>Within participant comparison of basal (fasting) [capillary-venous] glucose gradient, with the post prandial [capillary-venous] glucose gradient. </comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>[Capillary -venous] glucose gradient, at the two hour post prandial time point. Duplicate capillary and venous glucose measurements will be assessed using two meter/strip systems with differing enzyme systems, namely the Nova StatStrip and the Accu-chek Performa. Venous plasma glucose will also undergo rapid plasma separation using a PST tube, followed by laboratory measurement using the hexakinase method and this venous value will be used as an ancillary measure of [capillary-venous] difference.    
 </outcome>
      <timepoint>Two hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>[Capillary -venous] glucose gradient, at the one hour post prandial time point. Assessment of glucose is otherwise identical to that of the primary outcome (StatStrip and Performa glucose meters used to measure both capillary and venous samples,with a further check of venous glucose, undertaken by measuring plasma glucose in the laboratory).    </outcome>
      <timepoint>One hour</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 1 diabetes, HbA1c &lt;65mol/mol, on CSII or MDI insulin, ability to estimate insulin:carbohydrate ratio </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Previous studies in healthy volunteers suggest that a minimum number to detect a significant [capillary - venous] glucose gradient is around 12 participants. It is anticipated that this gradient will be attenuated in the present of diabetes, hence the larger number of participants. The primary outcome is descriptive, however if a gradient is found, this will be correlated with a) breakfast insulin dose (u/kg) b) macronutrient intake of meal (breakfast) c) baseline glucose and d) percentage body fat.   </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>11/11/2013</anticipatedstartdate>
    <actualstartdate>18/11/2013</actualstartdate>
    <anticipatedenddate>2/03/2014</anticipatedenddate>
    <actualenddate>15/03/2014</actualenddate>
    <samplesize>40</samplesize>
    <actualsamplesize>43</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Helen Lunt</primarysponsorname>
    <primarysponsoraddress>Diabetes Centre, Canterbury District Health Board 
550 Hagley Ave
Riccarton
Christchurch 8001
</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Diabetes Christchurch
</fundingname>
      <fundingaddress>550 Hagley Ave 
Riccarton
Christchurch 8001  
</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Otago Christchurch</sponsorname>
      <sponsoraddress>2 Riccarton Ave
Christchurch Central 
Christchurch 8011</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In healthy volunteers, tissue uptake of glucose after a meal results in a glucose gradient between the capillary blood at the finger and venous blood at the level of the antecubital fossa. We hypothesise that a similar [capillary-glucose] gradient exists in type 1 diabetes patients. If it does, this has implications for calibration of continuous glucose monitors. It also has implications when considering capillary and venous samples to be bio-equivalent when defining hypoglycaemic events, for example during pharmaceutical trials in participants with type 1 diabetes.   </summary>
    <trialwebsite />
    <publication>I. Lee, H. Lunt,  H. Chan, H. Heenan, J. Berkeley, C. M. A. Frampton. Postprandial capillaryvenous glucose gradient in Type 1 diabetes: magnitude and clinical associations in a real world setting. Diabet Med 2015.
DOI: 10.1111/dme.13025</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
Wellington Central 
Wellington 6011
</ethicaddress>
      <ethicapprovaldate>30/10/2013</ethicapprovaldate>
      <hrec>13/STH/148</hrec>
      <ethicsubmitdate>9/10/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Helen Lunt</name>
      <address>Diabetes Centre 
550 Hagley Ave
Riccarton
Christchurch 8001</address>
      <phone>+64 3 3640860</phone>
      <fax>+64 3 3640171</fax>
      <email>helen.lunt@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Helen Lunt</name>
      <address>Diabetes Centre 
550 Hagley Ave
Riccarton
Christchurch 8001</address>
      <phone>+64 3 3640860</phone>
      <fax>+64 3 3640171</fax>
      <email>helen.lunt@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Helen Lunt</name>
      <address>Diabetes Centre 
550 Hagley Ave
Riccarton
Christchurch 8001</address>
      <phone>+64 3 3640860</phone>
      <fax />
      <email>helen.lunt@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Helen Lunt</name>
      <address>Diabetes Centre 
550 Hagley Ave
Riccarton
Christchurch 8001</address>
      <phone>+64 3 3640860</phone>
      <fax />
      <email>helen.lunt@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>